Chimeric Therapeutics Ltd
Company Profile
Business description
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.
Contact
62 Lygon Street
Level 3, Carlton
MelbourneVIC3053
AUST: +61 398245254
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
Stocks News & Analysis
stocks
6 undervalued US shares that crushed earnings
stocks
Undervalued REIT offers attractive yield post earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,274.20 | 5.60 | 0.06% |
| CAC 40 | 8,532.05 | 47.55 | -0.55% |
| DAX 40 | 26,201.71 | 136.90 | -0.52% |
| Dow JONES (US) | 53,427.77 | 32.01 | -0.06% |
| FTSE 100 | 10,766.89 | 46.59 | 0.43% |
| HKSE | 25,471.15 | 17.92 | 0.07% |
| NASDAQ | 26,313.78 | 331.13 | -1.24% |
| Nikkei 225 | 67,460.73 | 1,759.52 | -2.54% |
| NZX 50 Index | 13,866.18 | 144.20 | 1.05% |
| S&P 500 | 7,704.95 | 40.11 | -0.52% |
| S&P/ASX 200 | 9,070.00 | 5.20 | 0.06% |
| SSE Composite Index | 3,990.30 | 7.65 | 0.19% |